Nuvectis Pharma (NVCT) investor relations material

Introduction and agenda

• Discussion focused on the NXP900 phase 1b program in advanced solid tumors, including combination with osimertinib in non-small cell lung cancer, with participation from key scientific and clinical leaders.

• Agenda included a review of NXP900's mechanism, preclinical and clinical data, KOL presentations, and a Q&A session with investors and analysts.

KOL background and credentials

• Dr. Asier Unciti-Broceta, co-inventor of NXP900, is a professor and director at the University of Edinburgh, with expertise in medicinal chemistry and cancer drug development.

• Dr. Alexander Spira, Chief Scientific Officer at Next Oncology, is a leading clinical oncologist specializing in thoracic cancer and phase I trials.

• Speakers included Ron Bentsur (CEO), Prof. Asier Unciti-Broceta, and Dr. Alexander Spira.

Market insights and analysis

• NXP900 targets a large addressable population, estimated at 45,000 patients in non-small cell lung cancer alone.

• NSCLC treatment paradigms highlight significant unmet needs, especially in second-line where survival outcomes with docetaxel remain poor.

• FLAURA2 and MARIPOSA studies show evolving standards in EGFR-mutated NSCLC, with persistent gaps post-progression.

• Substantial opportunity exists for new oral therapies, especially for patients with recurrent disease and specific genetic alterations.

• Current standard therapies for EGFR-mutated lung cancer have significant toxicity and limited durability, with unmet needs in both first- and second-line settings.